OpenAI Launches GPT-Rosalind for Drug Discovery

OpenAI has released GPT-Rosalind, its first AI model built specifically for life sciences research. Named after Rosalind Franklin, the scientist whose X-ray work was critical to discovering DNA’s structure, the model is designed to accelerate drug discovery, genomics, and translational medicine.

What Makes It Different

Unlike ChatGPT’s general-purpose approach, GPT-Rosalind was trained on 50 specific biological workflows. It can query specialised databases, parse recent scientific papers, interact with computational biology tools, and suggest new experimental pathways — all within a single interface.

Crucially, it’s designed to push back. Where a general model might enthusiastically endorse any hypothesis, OpenAI says GPT-Rosalind will reject poor drug targets and question weak experimental connections. That kind of critical reasoning is what researchers actually need.

On BixBench, a benchmark for real-world bioinformatics tasks, GPT-Rosalind scores 0.751, ahead of GPT-5.4 (0.732) and Gemini 3.1 Pro (0.550). On LABBench2, which covers protocol design and molecular cloning, it outperforms GPT-5.4 on six of eleven tasks.

Who Gets Access

This is not a consumer product. GPT-Rosalind is available through OpenAI’s trusted-access program, starting with US-based enterprise customers. The first partners are Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific.

OpenAI is also launching a Life Sciences plugin for Codex that connects to over 50 scientific tools and data sources, giving researchers programmatic access to biological databases through a developer interface.

What This Means for You

If you work in biotech or pharma, GPT-Rosalind could meaningfully speed up early-stage research — from literature reviews to experiment design. For everyone else, it signals a broader shift: AI companies are moving beyond general-purpose chatbots toward specialised models trained for specific professional domains.

This follows a busy week for AI model releases, including Anthropic’s Claude Opus 4.7 on the same day. To keep up with the latest AI tools, check out our newsletter.